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Angiotensin converting enzyme inhibitor-induced renal dysfunction in
atherosclerotic renovascular disease. Ischemic nephropathy due to bilat-
eral renovascular disease (RVD) is increasingly recognized as cause of
end-stage renal failure in the elderly, but a reliable non-invasive method of
detection is not available. Angiotensin converting enzyme inhibition
(ACEi) may impair renal function in such patients, but a prospective study
of its diagnostic validity has not been undertaken. We studied the effects
of controlled exposure to ACEi on plasma creatinine in 108 patients at risk
for severe bilateral atherosclerotic RVD, and compared the findings with
subsequent angiography. ACEi was given for two weeks, or, to avoid acute
renal failure, for four days if plasma creatinine had increased by 20% or
more. If after two weeks of ACEi plasma creatinine had not increased
by $ 20%, while blood pressure was still elevated, plasma creatinine was
remeasured after blood pressure control by addition of diuretics. The
severity of RVD was scored by the stenosis grade of the best perfused
kidney. Fifty-two patients had severe bilateral RVD, defined as $ 50%
stenosis to both kidneys (N 5 23) or a solitary functioning kidney (N 5
29). Of the others, 21 had less severe bilateral RVD, 20 unilateral RVD,
and 15 no apparent RVD. Basal plasma creatinine was higher in severe
bilateral RVD (median 170 mmol/liter, range 85 to 654 mmol/liter) than in
the others (122 mmol/liter, 62 to 675 mmol/liter; P , 0.01), but not
discriminative due to a large variability. The increase during ACEi was
correlated with the degree of RVD (r 5 0.53, P , 0.001). In 69 patients
ACEi caused at least a 20% increase in plasma creatinine, in 26 cases by
four days, in 31 after two weeks, and in 12 only after blood pressure
control by diuretics. Among these were all 52 patients with severe bilateral
RVD, 15 of the 41 patients with lesser forms of RVD, and two with normal
renal arteries. Thus, in this selected population the criterion of $ 20% rise
in plasma creatinine upon ACEi was 100% sensitive to detect severe
bilateral RVD, while its specificity was 70%. No case of acute renal failure
was encountered, and plasma creatinine always recovered after stopping
ACEi. In conclusion, controlled exposure to ACEi in these patients is safe,
and ACEi-induced increase in plasma creatinine is a very sensitive
detector of severe bilateral RVD in a high risk population.
Detection and treatment of renal artery stenosis focuses mainly
on its role as a hypertensive mechanism. However, atherosclerotic
renovascular disease (RVD) is progressive [1, 2], and increasingly
recognized as a major cause of end-stage renal failure. At least
15% of elderly patients requiring dialysis treatment do so because
of RVD [3–5], but the disease is probably underdiagnosed [3, 6].
Once on dialysis, these patients have a worse prognosis than the
general dialysis population [7]. Surgery and transluminal angio-
plasty [8, 9] are used to prevent progression of ischemic nephrop-
athy, with variable results and complication rates [1]. Recently, we
[10] and others [11, 12] have reported on renovascular stent
placement to protect the kidneys from ongoing ischemic damage.
Obviously, our first concern should be detection of the patients at
risk for severe bilateral RVD, including severe stenosis to a
solitary functioning kidney.
Whereas tests for the detection of unilateral stenosis such as
angiotensin converting enzyme inhibitor (ACEi) renography [13–
15] or ACEi-stimulated plasma renin activity [13, 16] have been
well validated, no standard methods exist to distinguish patients
with hemodynamically significant bilateral RVD. Such patients
may demonstrate a drop in kidney function after starting ACEi
[17, 18], but it is unknown whether this can be used prospectively
to detect RVD. Although ACEi-induced renal dysfunction can
also occur in patients with nephrosclerosis [19], that is, with renal
perfusion impairment inaccessible to direct treatment, it is valu-
able to know whether this phenomenon can be utilized to detect
at least those patients with potentially reversible forms of RVD.
Limited data are provided by two retrospective studies. In one,
a significant increase in serum creatinine (. 0.3 mg/dl) was found
in only 27% of 136 patients with bilateral RVD [20, 21]. The other
analysis of 19 patients with either bilateral stenosis or stenosis to
a solitary kidney showed ACEi-induced renal dysfunction (serum
creatinine increase 2 to 3 times baseline) in 32% [22]. However,
these studies, which were designed for another purpose, did not
provide details on the grade of stenosis nor did they take the
volume status into consideration. Volume retention, the inevita-
ble sequel of severe bilateral RVD [23], tends to normalize renal
perfusion pressure and renin production, thereby obviating ACEi-
induced renal impairment [17, 24]. This may become apparent
from the absence of a blood pressure response to ACEi.
The urgency of this matter relates not only to the severe
consequences of bilateral atherosclerotic RVD, but also to the
fact that many, if not all, of these patients will receive ACEi as
part of their regular antihypertensive treatment [1, 17, 21, 24]. We
therefore prospectively studied whether changes in renal function
following ACEi can be used to unmask patients with significant
bilateral RVD among subjects at risk. Special attention was paid
to the grade of the stenoses, and the role of blood pressure
normalization during ACEi. We also took care to keep increments
Key words: angiotensin converting enzyme inhibition, atherosclerosis,
hypertension, ischemic nephropathy, renal artery stenosis, renal failure.
Received for publication April 2, 1997
and in revised form October 28, 1997
Accepted for publication October 28, 1997
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 986–993
986
of plasma creatinine within limits, by stopping ACEi sooner in
patients showing an early rise in plasma creatinine.
METHODS
Patients
Our clinic is a tertiary referral center for the treatment of
renovascular disease. From 1993 newly referred patients meeting
the study criteria [age $ 45 years, hypertension (blood pressure .
160/95 mm Hg while treated or untreated)], and at least one of
four other criteria [clinically significant coronary atherosclerosis,
cerebrovascular disease, peripheral atherosclerosis, or renal dys-
function (plasma creatinine $ 120 mmol/liter) with no obvious
cause], were invited to participate. The study, approved by the
Hospital Ethical Committee, and performed after obtaining in-
formed consent, involved controlled administration of an angio-
tensin I converting enzyme inhibitor (ACEi), followed by an
intra-arterial subtraction angiogram. One hundred and eight
patients, 59 males, mean age 63 years (range 45 to 79) were
included. The known duration of hypertension averaged 8.3 years
(range 0 to 40 years); 78 were smokers, seven had type 2 diabetes
mellitus. Antihypertensive medication at entry of the study in-
cluded four classes of drugs in three patients, three classes in 28
patients, two classes in 42 patients, and one class in 30 patients.
Diuretics were used by 63 patients, and b-blockers by 45 patients.
Five patients did not take antihypertensive medication.
Administration of angiotensin converting enzyme inhibitors
Patients not taking ACEi at the time of referral (N 5 94) were
given enalapril 10 mg b.i.d., or a lower dosage depending on
plasma creatinine level (plasma creatinine 150 mmol/liter to 250
mmol/liter, 10 mg enalapril o.d.; plasma creatinine $ 250 mmol/
liter, 5 mg enalapril o.d.). All previous antihypertensive medica-
tions were continued. Blood pressure and plasma creatinine levels
were measured after four days and two weeks.
Enalapril was discontinued after four days if plasma creatinine
had increased by 20% or more, but otherwise it was continued for
two weeks. This margin was based on previous studies in which a
minimum increase in plasma creatinine during ACEi of ;20%
was considered significant [21, 25]. As mentioned above, we paid
special attention to the role of the volume status in judging the
renal response to ACEi, since hypervolemia can suppress renin
and thus desensitize patients to the effects of ACEi even in case
of bilateral renal artery stenosis [17, 23]. The blood pressure
response was used to assess the volume status. This was done as
follows. If, after two weeks of ACEi, blood pressure was still
elevated [. 160/95 mm Hg, or mean arterial pressure (MAP) .
117 mm Hg; MAP 5 diastolic pressure plus one-third of the pulse
pressure], the next step depended upon plasma creatinine. If the
plasma creatinine had increased by at least 20%, this was consid-
ered a significant increase, and ACEi was stopped; however, if
plasma creatinine had not changed or increased less than 20%,
furosemide was added until blood pressure was below this crite-
rion, after which plasma creatinine was reassessed. During this
period the patients were seen twice weekly. The starting dose of
furosemide was 40 mg twice daily, to be increased to 80 mg twice
daily, and occasionally further, if blood pressure did not respond
sufficiently. Patients who developed hypotension during enalapril
treatment (systolic blood pressure , 120 mm Hg), received
sodium chloride (2 liters of saline i.v.) to increase blood pressure
above this level before plasma creatinine was measured. In all
other situations, plasma creatinine after two weeks of ACEi was
used for the evaluation. Fourteen patients were using an adequate
dosage of ACEi for at least two weeks at the time of referral. In
those patients, the effects of ACEi were evaluated by stopping
ACEi for two weeks. Evaluation of ACEi effects were largely
performed on an outpatient basis (N 5 85).
Plasma creatinine was measured by an enzymatic method,
eliminating measurement of spurious non-creatinine chromogens
[26]. The coefficient of variation for the plasma creatinine deter-
mination was 4%. Blood samples were taken in the morning with
the patients fasting or after a breakfast, which excluded a major
effect of meals on plasma creatinine [27].
Angiography
Renal intra-arterial subtraction angiography was performed
using standard techniques and a midstream aortogram was made
in several different projections. The presence and degree of
stenosis were scored in percentage independently by two radiol-
ogists, and averaged to the nearest decade. The angiography was
performed within one month after completion of the ACEi
evaluation as described above.
Evaluation of the data
As explained further in the Discussion section, we scored the
severity of RVD as the grade of stenosis in the best perfused
kidney, hypothesizing that this determines the main defense
against renal dysfunction during ACEi [1]. Patients with stenosis
to a solitary functioning kidney were scored similarly, and by
definition were considered to have bilateral RVD. We defined
renal artery stenosis as severe if the diameter reduction on the
angiogram was at least 50%. This corresponds with a luminal area
reduction of ;75% [28], which is considered hemodynamically
relevant [28, 29]. The relationship between ACEi-induced plasma
creatinine increase and severity of RVD was assessed with the
Spearman rank order correlation test. Differences between pa-
tients with and without severe bilateral RVD were assessed with
the Mann-Witney rank sum test.
RESULTS
Effects of angiotensin converting enzyme inhibition on renal
function
In 26 patients plasma creatinine had increased by at least 20%
after four days of enalapril (median increase 42%, range 22 to
98%), so that enalapril was stopped in accordance with the
protocol. Median values for plasma creatinine were 157 mmol/liter
without ACEi, and 239 mmol/liter during ACEi (Table 1). All
these patients except two were normotensive according to the
upper blood pressure criterium of 160/95 mm Hg (or mean
arterial pressure of 117 mm Hg). The median values before and
during ACEi are given in Table 1.
Of the other patients, evaluated two weeks after starting ACEi
or stopping maintenance ACEi, 31 showed a change in plasma
creatinine of $ 20% (median elevation during ACEi 37%, range
23 to 63%). Median values for plasma creatinine were 183
mmol/liter without ACEi, and 257 mmol/liter during ACEi. Of
these patients, 5 had remained hypertensive. The median blood
pressure in these 31 patients with and without ACEi is given in
Table 1.
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In 51 patients plasma creatinine had not changed according to
the preset criterion of a 20% increase. Of these subjects, 36 were
normotensive during ACEi (Table 1). Their median plasma
creatinine without ACEi was 115 mmol/liter and during ACEi 121
mmol/liter, and the median change was 7% (range 216 to 18).
The other 15 patients in this group had remained hypertensive.
Their median plasma creatinine was 134 mmol/liter without ACEi
and during ACEi 142 mmol/liter, and the median change 5%
(range 26 to 18%). These subjects received additional furosemide
in accordance with the protocol. In twelve of these plasma
creatinine rose by $ 20%, whereas three became normotensive
without showing such a change in plasma creatinine. Median
values for all 15 patients (without ACEi, with ACEi alone, and
with ACEi plus furosemide) are given in Table 1. Of the twelve
patients who showed the $ 20% increase in plasma creatinine
(median change 34%, range 21 to 101%), three had remained
hypertensive. Figure 1 illustrates the data in these twelve patients
separately.
Two of these 51 patients showed a transient increase in plasma
creatinine during hypotension that was induced by enalapril. Both
patients received volume repletion, which restored their blood
pressure and plasma creatinine levels. The respective values of
blood pressure and plasma creatinine in one patient were 180/100,
100/70, and 120/80 mm Hg, and 167, 233, and 186 mmol/liter, and
in the other patient 170/115, 90/65, and 120/85 mm Hg, and 73,
122, and 83 mmol/liter.
The 14 patients who were using ACEi at the time of referral
were all taking additional antihypertensives. Eleven were normo-
tensive, and became hypertensive after stopping ACEi. Of these,
eight showed $ 20% increase in plasma creatinine. Three patients
were hypertensive at referral. They remained so after stopping
ACEi, but developed $ 20% increase in plasma creatinine. This
behavior was not different from that in the others, and the results
were evaluated in aggregate.
In total, 69 patients had developed at least 20% increase in
plasma creatinine during ACEi treatment. This excludes the two
patients who had a transient increase related to hypovolemia.
Importantly, none of the patients experienced oliguric acute renal
failure and, in all patients in whom plasma creatinine rose by at
least 20% after starting enalapril (N 5 58), this change appeared
to be completely reversible (plasma creatinine before enalapril
160 mmol/liter, 85 to 654 mmol/liter; after stopping enalapril 158
mmol/liter, 87 to 655 mmol/liter).
Fig. 1. Systolic and diastolic blood pressure (A) and plasma creatinine (B)
in 12 patients in which angiotensin converting enzyme inhibition (ACEi)
caused an increase in plasma creatinine (> 20%) only after lowering the
blood pressure with a diuretic. Data are presented as median 6 quartiles.
Table 1. Division of patients according to course of plasma creatinine during angiotensin converting enzyme (ACE) inhibition
Category
according to
change in plasma
creatinine
Patient number Plasma creatinine mmol/liter
Blood pressure mm Hg
Number with
severe
bilateral
RVDSystolic Diastolic MAP
N Median 25%–75% Median 25%–75% Median 25%–75% Median 25%–75% N
$ 20% rise in 4 26 Without 157 124–180 193 180–210 100 95–110 133 123–143 20
days With ACEi 239 170–300 150 140–165 80 80–90 105 100–113
$ 20% rise in 2 31 Without 183 135–273 190 170–210 100 95–110 130 121–140 21
weeks With ACEi 257 183–363 150 140–160 85 80–90 105 100–113
, 20% rise in 2
weeks
Normotensive 36 Without 115 92–186 180 160–195 100 90–110 125 117–133 0
With ACEi 121 93–197 150 140–160 85 80–90 107 99–113
Hypertensive 15 Without 134 98–197 215 181–220 110 100–120 140 131–153 11
With ACEi 142 105–228 190 190–210 100 100–110 130 120–143
ACEi 1 Furo 176 129–303 140 140–175 85 80–88 107 100–118
Data are expressed as median and interquartile range (25%–75%). Abbreviations are: RVD, renovascular disease; N, number; MAP, mean arterial
pressure.
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Relationship of angiotensin converting enzyme inhibitor
response to severity of renal artery stenosis
Considering at least 50% arterial narrowing as severe stenosis,
52 patients had severe bilateral renal artery stenosis, that is, either
unilateral $ 50% stenosis and contralateral renal artery occlusion
(N 5 27) or $ 50% stenosis to single kidney (N 5 2), or by
bilateral $ 50% stenosis (N 5 23). Of the remaining 56 subjects,
15 had bilateral normal renal arteries, 20 had unilateral normal
arteries with contralateral modest stenosis (, 50%, N 5 4), severe
stenosis (N 5 13) or occlusion (N 5 3), three had modest bilateral
stenosis, and 18 had modest unlilateral stenosis with contralateral
severe stenosis (N 5 13) or occlusion (N 5 5).
To study the relationship between the plasma creatinine re-
sponse to ACEi and the severity of renovascular disease, we
scored the patients by the severity of the least stenosis. When
scored in this way, the grade of renal artery stenosis was weakly
but significantly correlated with the percent rise in plasma creat-
inine caused by ACEi (Fig. 2; r 5 0.53, P , 0.001). However, given
the wide variation of data in both patients with severe bilateral
renal artery stenosis as well as in patients without significant
bilateral stenosis, this correlation is of limited relevance. In
addition, early stopping of enalapril in case of a rapid rise in
creatinine probably influenced this correlation.
The 69 patients in whom plasma creatinine had increased by at
least 20% during ACEi treatment included all 52 cases of severe
bilateral RVD (median change in this group 38%, range 21 to
101%). A plasma creatinine rise of at least 20% was also found in
15 of the 41 patients (37%) with lesser grades of bilateral RVD or
with unilateral RVD, and in 2 of the 15 patients (13%) with
bilateral normal renal arteries. In aggregate, this means that in the
present population and with the present method of controlled
ACEi, application of $ 20% rise in plasma creatinine as the
deciding criterion had a 100% sensitivity and a 70% specificity to
detect severe bilateral RVD or severe RVD in a single functioning
kidney, and yielded a false positive result in 25%. The use of lower
margins in plasma creatinine increase did not affect sensitivity
(being 100%), but reduced specificity to 68% (17% increase
margin), 63% (14% margin), and 48% (10% margin).
Four further points deserve mentioning. First, of the 26 patients
showing a significant rise in plasma creatinine within four days of
enalapril, 23 had at least 30% stenosis (20 at least 50% stenosis)
in their best perfused kidney (Table 1). Second, of the 12 patients
who showed a $ 20% increase in plasma creatinine only after
blood pressure correction by the addition of furosemide to ACEi,
11 had severe bilateral RVD. Both subsets are separately indi-
cated in Figure 2. Third, of the two hypotensive patients in whom
the increase in plasma creatinine was restored after volume
repletion, one had significant unilateral stenosis, and the other no
apparent RVD. Fourth, it deserves mentioning that b-blockers,
which were continued during the study, were used by 27 of the 52
patients with severe bilateral RVD, and by 18 of the 56 others.
We also considered basal plasma creatinine as an indicator of
severe bilateral RVD in the present group of patients. Median
plasma creatinine was indeed significantly higher in the 52 pa-
tients with severe bilateral RVD (170 mmol/liter, range 85 to 654)
than in the 56 patients with lesser grades or absent bilateral RVD
(median 122 mmol/liter, 62 to 675 mmol/liter; P , 0.01), but this
criterion was not discriminative due to the large overlap (Fig. 3).
The patients showing a $ 20% increase in plasma creatinine in
this group (‘false positive results’) showed a similar variation in
Fig. 2. Individual changes in plasma creatinine during angiotensin con-
verting enzyme inhibition (ACEi) plotted against the stenosis grade of the
best perfused kidney in all 108 patients studied. Symbols are: (M) patients
in whom ACEi was stopped after four days since plasma creatinine had
increased by $ 20% (N 5 26); () patients in whom plasma creatinine was
measured after addition of diuretics to ACEi to control blood pressure
(N 5 15); (E) all other patients.
Fig. 3. Individual data of plasma creatinine in the absence of angiotensin
converting enzyme inhibition (ACEi) in patients with severe bilateral
renal artery stenosis (> 50% stenosis to the best perfused kidney or to
solitary kidney; N 5 52) and in the patients with lesser grades or absent
renovascular disease (N 5 56). For the latter group, patients displaying $
20% increase in plasma creatinine during ACEi (N 5 17) have been
denoted in closed symbols.
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basal plasma creatinine (Fig. 3; median 154 mmol/liter, range 90 to
425 mmol/liter).
Finally, we evaluated whether the basal and final blood pres-
sures were different in the patients with and without a $ 20%
increase in plasma creatinine. In the 52 patients with the 20%
increase who also had severe bilateral RVD (true positives), the
median value for MAP was 132 mm Hg (range 107 to 160 mm Hg)
without ACEi and 103 mm Hg (80 to 130 mm Hg) during ACEi.
In the other 17 patients showing that increase (false positives), the
MAP was 135 mm Hg (108 to 160 mm Hg) without ACEi and 107
mm Hg (93 to 128 mm Hg) during ACEi. In the remaining 39
patients (true negatives) the median values for the MAP were 127
mm Hg (97 to 167 mm Hg) without ACEi and 107 mm Hg (87 to
117 mm Hg) during ACEi. The values of MAP with and without
ACEi were not significantly different between any of these groups.
A similar evaluation for systolic and diastolic pressures (not given)
also revealed no differences.
DISCUSSION
This is the first prospective study testing whether a rise in
plasma creatinine during ACEi can unmask severe bilateral RVD
among patients at risk. Timely detection of such patients is a
prerequisite to preserve the renal circulation by surgical or
radiological intervention, since such patients are prone to develop
terminal renal failure by progressive renal ischemia [1–6, 30, 31].
We found that all patients with severe bilateral RVD, defined as
a $ 50% stenosis in the artery of the best perfused kidney, or to
a solitary kidney, showed some elevation of plasma creatinine, at
least 20%. Such an increase also occurred in patients with lesser
grades of bilateral RVD, unilateral RVD, or normal renal arter-
ies, but not as often.
The incidence of oliguric renal failure following ACEi in
patients with bilateral RVD is limited to a few percent [1, 17, 21].
Nonetheless, it is considered a serious side effect, and it is of
prime concern to apply ACEi cautiously. Therefore, our protocol
required stopping ACEi sooner in patients showing a rapid rise in
creatinine. Conceivably, this policy led to some loss of informa-
tion, as we missed the maximum rise in plasma creatinine as an
indicator of the severity of RVD (Fig. 2). Yet, it successfully
unmasked severe bilateral RVD, which was apparent in most of
these patients. Despite the high prevalence of severe bilateral
RVD in this series, controlled ACEi administration as presently
applied was safe: the decrease in renal function was limited and
was fully reversible.
Since all patients with severe bilateral RVD manifested at least
20% decrease in renal function during ACEi, the first conclusion
that we can draw is that this criterion had 100% sensitivity for the
detection of such patients. Second, since the median rise in
plasma creatinine was only 38%, we can also conclude that such a
modest increase in plasma creatinine should not be discounted as
meaningless, and in fact should raise serious suspicion of severe
bilateral RVD. To ignore such a modest increase in plasma
creatinine, as has been the general policy [17, 21], implicates a
failure to appreciate ischemic RVD at a stage where this is
possibly remediable. The latter is highly relevant, as hypertensive
patients with signs of atherosclerosis will often be treated with
ACEi.
Three previous studies provide data on the sensitivity of
ACEi-induced renal dysfunction as indicator for bilateral RVD
(or unilateral stenosis to a solitary kidney) [20, 22, 32]. On
average, only about one third of the cases developed some degree
of renal dysfunction during ACEi, against 100% of the patients
with severe bilateral RVD in the present study. It should be
stated, however, that these studies focused on safety aspects of
ACEi and were not specifically designed to detect ischemic
nephropathy. Nonetheless, the disparity with the present data
illustrates the necessity to closely define such patients with respect
to volume status and grade of stenosis [17]. In previous reports the
role of sodium balance or blood pressure in individuals was not
considered in the evaluation of the renal response [20, 22], and
details on the grade of stenosis (specifically in the “negative”
patients) were absent [20, 22, 32]. This, however, is understand-
able since these multicenter [20, 32] and retrospective [20, 22]
studies were carried out for another purpose.
The role of sodium balance is underscored by the clinical
observation that diuretics increase the risk of renal failure by
ACEi in patients with bilateral RVD [33]. In fact, ACEi-induced
renal failure has been shown to resolve after stopping diuretics
[24, 34], and lack of ACEi-induced renal dysfunction in sodium-
replete subjects does not exclude severe bilateral RVD [17]. It
should be realized that advanced bilateral renal artery stenosis
inevitably elicits sodium retention. Acute pulmonary edema, a
recently recognized manifestation of severe bilateral RVD [35],
illustrates this fact. By elevating arterial pressure, sodium reten-
tion can eventually normalize renal perfusion pressure and renin
release, and decrease the susceptibility to ACEi-induced renal
dysfunction. In that case, blood pressure may still be elevated
despite ACEi. Therefore, we took special care to lower blood
pressure levels below a certain (high normal) standard by the
addition of diuretics in patients in whom two weeks of ACEi had
no significant effect on plasma creatinine, while blood pressure
was still elevated. Remarkably, most patients in whom this
procedure was followed not only developed a significant increase
in creatinine, but also appeared to have severe bilateral RVD.
Lack of co-evaluation of individual blood pressure responses
may clearly have played a role in the relatively low incidence of
ACEi-induced renal dysfunction in previous reports [20, 22].
Notably, the actual prevalence of such patients may be higher than
in our series, since many of the present patients already received
diuretics when they started ACEi. The other side of this coin is
that true volume depletion increases sensitivity to ACEi also in
the absence of RVD. In that case, one may anticipate that renal
dysfunction caused by ACEi will be accompanied by hypotension,
similar to the situation found in heart failure [36] or gastrointes-
tinal fluid loss [37]. Indeed, two patients in our series without
severe bilateral RVD developed hypotension and renal dysfunc-
tion, which resolved after volume repletion. In view of these
considerations, it is also important to acknowledge that basal and
final blood pressures in the patients displaying the $ 20% plasma
creatinine increase, whether with or without severe bilateral
RVD, were not different from those who did not show that
increase. Thus, it is unlikely that the different responses or the
false positive results were induced by different changes in blood
pressure.
In patients with unilateral renal artery stenosis, ACEi often
decreases perfusion and filtration in the affected kidney, and
increases perfusion without altering filtration in the non-affected
kidney [38–40]. In dogs with two-kidney, one-clip hypertension a
similar pattern has been found [41]. In two-kidney, one-clip
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hypertensive rats ACEi can even increase filtration in the con-
tralateral kidney [42, 43]. This was also reported in a few patients
[38]. In general, it is fair to assume that the net decrease in
glomerular filtration following ACEi will depend upon the bal-
ance between the fall in filtration in ischemic nephrons, and the
unchanged or perhaps increased filtration in non-ischemic
nephrons. Since the latter depends upon the perfusion of the best
kidney, we defined the severity of bilateral RVD as the grade of
stenosis in the best perfused kidney. Undoubtedly, this consistent
approach has played a major role in the current consistent finding
of ACEi-induced renal dysfunction in severe bilateral RVD,
defined as having at least 50% stenosis in the best perfused
kidney. Previous studies, which failed to define patients to the
grade of stenosis in the best perfused kidney, found a much lower
rate of ACEi-induced rise in plasma creatinine [20, 22, 32]. In
patients with bilateral RVD, but lesser grades of stenosis in their
best perfused kidney, we found the same lower frequency of this
complication. By contrast, in the few reported patients in whom
the grade of stenosis in bilateral RVD or of the stenosis to a
solitary kidney was explicitely mentioned as being severe, prospec-
tive evaluation of ACEi was virtually always associated with a
significant decrease in renal function [44–46].
The 48% prevalence of severe bilateral RVD in the present
series seems somewhat high, but is not extraordinary. The prev-
alence of renovascular hypertension in patients with clinical clues,
selected for diagnostic validity studies, varies from 20 to 50% [13].
As summarized by others [1], about half the patients with RVD
have bilateral disease in autopsy surveys [47, 48] and large
angiographic surveys [49–51]. Three recent large surveys in
patients selected using similar criteria as those in the present
series found severe bilateral RVD by angiography in 13% [50],
18% [52] and 25% [13]. The difference with the present series may
relate to the difference in angiographic criteria for severe RVD,
which was 75% stenosis in the above series, and 50% in ours. Had
we used that criterium, about 22% of the patients would have had
severe bilateral RVD (Fig. 2). We used the 50% criterion since
that is considered hemodynamically relevant [28, 29].
Study of ACEi-induced renal dysfunction as described here
helps to quantify the severity of renal perfusion impairment, but
can of course not discern whether this concerns extrarenal or
intrarenal vessels. ACEi-induced renal dysfunction has been
described in some patients with nephrosclerosis and normal main
renal arteries [19]. Nephrosclerosis, secondary to long-standing
hypertension [53], can be variably expected in patients with RVD.
Therefore, ACEi-induced renal dysfunction can be anticipated in
patients with severe bilateral RVD, as well as in patients with
lesser grades of RVD complicated by nephrosclerosis [20, 25, 32].
Clearly, patients of the latter kind will be among subjects selected
for clinical suspicion of severe bilateral RVD, and the modest
70% specificity and the 25% of false positives found when one
applies the criterion of $ 20% rise in plasma creatinine, is not
unexpected. Our data imply that, if one would use this criterion to
select patients for angiography within a high risk group, about
30% of patients without severe bilateral RVD (that is, 17 out of 56
patients), would be exposed to the risks of angiography [54, 55].
On the other hand, most of these “false positive” patients had
some grade of bilateral or unilateral RVD. It seems likely that in
these patients the severity of the renal ischemia is larger than that
indicated by the stenosis, perhaps due to the additional effects of
a compromized intrarenal circulation by nephrosclerosis, or due
to some other cause. In fact, these patients also suffer from
ischemic nephropathy, and it can be defended that the clinical
approach to these patients, that is, to protect the circulation to the
kidneys, should not be different from that in patients with more
severe bilateral RVD.
Whether the presently described ACEi test is useful for the
detection of ischemic nephropathy in less selected populations
remains to be seen. Several points are relevant. First, it is likely
that the specificity of the test will improve in less selected
populations, since the number of patients with truly normal
kidneys will increase. Second, no other prospective data are
available to confirm the presently found 100% sensitivity in a high
risk group, nor whether this can be maintained in less selected
populations. If our data can be confirmed, they imply that
lowering the criterium of 20% plasma creatinine increase will not
improve sensitivity, but decrease specificity. The latter, however,
must be weighed against the possibility that also more patients
with (combinations of) nephrosclerosis and lesser degrees of renal
artery stenosis may be detected. Third, whereas it is known that
atherosclerotic RVD is not well treatable with transluminal
angioplasty, two recent studies have shown that placement of
intra-arterial stents can successfully avert deterioration of renal
function [11, 12]. We have shown, in a limited number of subjects
with unilateral stenosis and contralateral occlusion, that unilateral
stent placement can make residual renin-dependent hypertension
manageable with ACEi; the deterioration of renal function that
occurred prior to stenting did not occur afterwards [10]. Given
that this successful remedy becomes available for larger patient
numbers, it will become profitable to detect patients with ischemic
nephropathy in a prospective manner. The question of whether
and in which population this would be cost-effective is clearly very
complicated, and beyond the scope of the present study. However,
we believe that the ACEi method is easily applicable, has low risk
and costs, and is very appropriate since administration of ACEi
will often be part of the regular treatment of hypertension.
There is no other way to obtain functional quantitative infor-
mation on the degree of renal perfusion impairment. Elevated
plasma creatinine, an often used selection criterion [17, 22, 56],
can clearly not discriminate between a renal ischemic disease due
to RVD or some other cause of renal dysfunction (Fig. 3).
ACEi-enhanced renography, whether using filtered or tubularly
extracted isotopes, is very appropriate to detect hemodynamically
significant unilateral renal artery stenosis, but loses accuracy in
cases of impaired renal function [13, 57] or bilateral stenosis [15,
56, 58]. Comparison of curve profiles before and after ACEi [57]
may improve the performance of ACEi-renography, but this
necessitates repeated renography. Study of the time course in
cortical hippurate activity during furosemide1ACEi-renography
has been shown to greatly improve the sensitivity and specificity
for RVD [59]. This approach is also particularly useful in patients
with renal insufficiency, but again requires repeated renography.
ACEi-stimulated plasma renin activity may be helpful to diagnose
renovascular disease in general, but is an unlikely option to
quantify the problem of the renal underperfusion [56]. Duplex
sonography techniques are being tested as non-invasive alterna-
tive for angiography to detect renal artery stenosis, but the results
are contradictory, and the sensitivity to detect ostial stenosis low
[13, 60, 61]. Besides, no functional information can be expected
from this technique. Compared to these methods, the ACEi test is
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relatively easy to perform, and apparently valuable to detect
patients with functional bilateral RVD.
The present study has limitations, some of which have been
outlined above. In addition to these, the limitations of angiogra-
phy to score the grade of stenosis must be considered. A relatively
large number of patients in both subsets continued to use a
b-blocker during the study. Although b-blockers are known to
suppress renin production [62], this presented no problem in the
interpretation of the ACEi effects. Furthermore, the chosen
cut-off point at two weeks was arbitrary, as the number of
published data on serial changes in plasma creatinine during
ACEi is limited [63]. Given the high sensitivity, this worked out
well, but we cannot exclude that a shorter follow-up period would
suffice. In many cases we stopped ACEi when a minimum of 20%
rise in plasma creatinine had been obtained. This implies that the
upper limit in plasma creatinine increase could not be used as an
independent variable to test the severity of the stenosis. Also, the
rise in plasma creatinine during ACEi appeared reversible, but we
did not study reproducibility of the ACEi-effect itself.
In conclusion, we found that renal dysfunction induced by the
controlled exposure to ACEi is a sensitive detector of severe
bilateral RVD in patients at risk, and that this exposure is a safe
procedure. It remains to be seen whether this ACEi test will select
those patients who will benefit from revascularization procedures
as far as progression of ischemic nephropathy is concerned. In
relation to this, it remains to be defined in which population this
test is cost-effective.
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